Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking…
Concert hopes to give Pfizer a run for its money in alopecia, while Reata looks to continue its renaissance with more Phoenix data.